Physiomics Plc
Physiomics are a leading oncology consultancy using proprietary state of the art Virtual TumourTM technology and other tools to predict and better understand the effects of cancer treatments. We work with partners developing cancer drugs to help them save time and money and achieve better outcomes during pre-clinical and clinical development. We are also developing tools to support cancer treatment in real world settings [Personalised Oncology]. Based in Oxford in the United Kingdom, Physiomics’ specialist oncology services are used by global pharmaceuticals as well as small biotech companies to support oncology R&D.
Company details
Find locations served, office locations
- Business Type:
- Consulting firm
- Industry Type:
- Pharmaceuticals
- Market Focus:
- Globally (various continents)
Our Vision
Physiomics’ vision is to transform oncology drug development. We believe in innovation, collaboration, diversity and inclusion and we aim to bring out the best in each other, in order to help our partners develop great cancer drugs and to apply them optimally in real-world settings.
How We Work?
We work with partners to solve real development and real-world treatment challenges and excel in combining knowledge of cancer with cutting-edge mathematics to develop models that help accelerate pre-clinical and clinical development.
We value open discussion and genuine collaboration, working with you to create bespoke solutions customised to your needs.
Our scientific consultants operate in agile teams that are responsive, flexible and adaptive, with experience working across large company structures as well as with smaller commercial and not-for profit clients.
Oncology Specialists
We’re 100% focused on oncology drug development with deep oncology modelling expertise, helping you save time and money.
Agile Teams
Our skilled teams are agile, collaborative and efficient. We work with you to solve real development challenges.
Industry & Academic Experience
Our team of experts have accumulated over 120 years of experience across pre-clinical and clinical pharmacology with a strong record of success.